Genicular artery embolisation for the treatment of symptomatic knee osteoarthritis
Learning Objectives
Author Block: F. N. N. Fleckenstein, B. Gebauer, B. Hamm, F. Collettini; Berlin/DE
Purpose: Genicular artery embolisation (GAE) is an innovative minimally-invasive therapy for patients with symptomatic knee osteoarthritis (OA) refractory to conservative treatments, aiming to reduce synovial arterial hypervascularity. This study aimed to evaluate the safety and efficacy of GAE for the treatment of symptomatic knee OA.
Methods or Background: A retrospective, single-centre study was conducted at our institution. Patients enrolled in the study were aged 40 to 90 years, had moderate to severe knee OA (Kellgren-Lawrence grade 2 to 4), and had previously experienced failure of conservative therapy. Baseline pain (assessed using the visual analog scale [VAS]) and symptom scores (Knee Injury and Osteoarthritis Outcome Score [KOOS]) were evaluated. After achieving femoral arterial access via a 4 Fr sheath, embolisation was performed using Imipenem/Cilastatin. Target vessels were determined using digital subtraction angiography in correlation with the patients' pain points. Adverse events and symptom scores were assessed at six weeks, three months, and six months after GAE.
Results or Findings: A total of 46 patients were enrolled, with a median age of 69 years (IQR, 61, 74). Knee OA severity was grade 2 in 12% of patients, grade 3 in 41%, and grade 4 in 47%. Technical success was achieved in 100% of procedures. Transient skin discoloration and transient mild knee pain after the procedure were noted in 18% of all cases, as expected. No complications were reported. The KOOS daily activity index and VAS improved by 87% and 71%, respectively, at six months from a median baseline of 57 (of 100) and 7 (of 10), respectively.
Conclusion: This retrospective study demonstrates that GAE is an effective and safe treatment for reducing OA-associated symptoms that are refractory to conservative therapy.
Limitations: This was a retrospective single-centre study, without a placebo or control arm.
Funding for this study: No funding was received for this study.
Has your study been approved by an ethics committee? Yes
Ethics committee - additional information: No information provided by the submitter.